Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
Subscribe To Our Newsletter & Stay Updated
